Dementia Drugs Market Report 2025 (Global Edition)

Global Dementia Drugs Market Report 2024 Market Size Split by Type (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, Other), by Drug Class (MAO Inhibitors, Glu...

Dementia Drugs Market Report Description

We have various report editions of Dementia Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Dementia Drugs Market Insights Video

Competitive Landscape of the Dementia Drugs Market

The competitive landscape of the Dementia Drugs market is characterized by a range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established drug manufacturers, specialized Dementia Drugs companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

April 2022: NovaMedica, a Russian pharmaceutical business (a RUSNANO investment project), has created and patented a unique combination of Donepezil and Memantine molecules, which are the primary treatments for dementia caused by Alzheimer's disease. MIOREO is the drug's registered name. This is the first time such a combination has occurred in the Russian market, as well as the EAEU and European markets. (Source: https://novamedica.com/media/our_news/p/12767-novamedica-launches-own-innovative-drug-for-the-treatment-of-alzheimers-disease) March 2022: Corium, Inc., a commercial-stage biopharmaceutical company focused on developing and commercializing novel CNS therapies, has received FDA approval for its ADLARITY (donepezil transdermal system) treatment for mild, moderate, or severe Alzheimer's dementia. ADLARITY is the first and only once-weekly patch that delivers regular dosages of donepezil through the skin, reducing the possibility of unfavorable gastrointestinal (GI) side effects associated with oral donepezil. ADLARITY is the first prescription medicine licensed to employ Corium's unique CORPLEX transdermal technology, which has been used in consumer products for many years. (Source: https://www.corium.com/pdf/Corium-FDA-ADLARITY-Approval-Press-Release.pdf) April 2024: Essential Pharma, an international specialty pharmaceutical group dedicated to ensuring patients' long-term access to low-volume, clinically differentiated, niche pharmaceutical products in key therapeutic areas, announces the completion of its acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company. Reminyl, a cholinesterase inhibitor, is an established central nervous system (CNS) medicine used to treat mild to moderately severe Alzheimer's dementia. Essential Pharma has acquired rights to Reminyl oral capsules in the European Economic Area, Thailand, South Korea, and all other present markets for that medicine, with the exception of the United Kingdom and Ireland, Japan, and Latin America. (Source: https://essentialpharmagroup.com/essential-pharma-announces-the-acquisition-on-reminyl-galantamine-hydrobromide-oral-capsules/)

Top Companies Market Share in Dementia Drugs Industry: (In no particular order of Rank)

• Johnson and Johnson
• Teva Pharmaceuticals
• Aurobindo Pharma
• Zydus Cadila
• Eli Lilly and Company
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Dementia Drugs Market

Which Region Dominates the Dementia Drugs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue due to the region's strong healthcare system and early diagnosis efforts, which have driven market growth. North America's commitment to investing in healthcare, such as drug development and patient care, has created a favorable environment for the dementia drugs market.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Dementia Drugs market due to the region's growing awareness about dementia and its symptoms, which is leading to earlier diagnosis and a greater demand for treatment options. Governments in the region are recognizing the increasing burden of dementia and are investing in research, awareness campaigns, and healthcare infrastructure.

The current report Scope analyzes Dementia Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Dementia Drugs Market

According to Cognitive Market Research, the global Dementia Drugs market size was estimated at USD 16215.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 6486.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Dementia Drugs market with a market size of USD 5117.52 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. The nation's increasing prevalence of dementia among an aging population.
• The Canada Dementia Drugs market had a market share of USD 778.33 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Canada's aging demographics and advancements in medical research.
• The Mexico Dementia Drugs market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 590.23 million in 2024.

Europe Dementia Drugs Market

According to Cognitive Market Research, the global Dementia Drugs market size was estimated at USD 16215.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 16215.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.0% from 2024 to 2031.

• The United Kingdom Dementia Drugs market had a market share of USD 817.25 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. In the UK, Dementia Drugs sales witness an upswing due to the nation's rising dementia diseases.
• The France Dementia Drugs market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 447.54 million in 2024.
• According to Cognitive Market Research, the German Dementia Drugs market size was valued at USD 963.18 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period. In Germany, Dementia Drugs surged due to the presence of major market players.
• The Italy Dementia Drugs market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 418.35 million in 2024.
• The Russia Dementia Drugs market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 754.01 million in 2024.
• The Spain Dementia Drugs market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 398.89 million in 2024
• The Luxembourg Dementia Drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 150.80 million in 2024.
• The Portugal Dementia Drugs market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 102.16 million in 2024.
• The Greece Dementia Drugs market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 58.37 million in 2024.
• Rest of Europe's Dementia Drugs market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 754.01 million in 2024.

Asia Pacific Dementia Drugs Market

According to Cognitive Market Research, the global Dementia Drugs market size was estimated at USD 16215.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 3729.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Dementia Drugs market size was valued at USD 1678.27 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. Dementia Drugs surged in China due to the adoption of various healthcare technologies.
• The Japan Dementia Drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 514.67 million in 2024.
• The India Dementia Drugs market had a market share of USD 447.54 million in 2024 and is projected to grow at a CAGR of 10.8% during the forecast period. India's supportive initiatives taken by the government.
• The South Korean Dementia Drugs market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 372.95 million in 2024.
• The Australian Dementia Drugs market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 193.93 million in 2024.
• The South East Asia Dementia Drugs market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 257.34 million in 2024.
• The Rest of Asia Pacific Dementia Drugs market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 264.79 million in 2024.

South America Dementia Drugs Market

According to Cognitive Market Research, the global Dementia Drugs market size was estimated at USD 16215.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 810.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Dementia Drugs market size was valued at USD 347.01 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Dementia Drugs flourished in Brazil due to the innovation in medications.
• Argentina's Dementia Drugs market had a market share of USD 136.21 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. Argentina's technological advancements in the healthcare industry augment the demand.
• Colombia's Dementia Drugs market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 72.16 million in 2024.
• Peru's Dementia Drugs market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 66.48 million in 2024.
• Chile's Dementia Drugs market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 58.37 million in 2024.
• The Rest of Latin America's Dementia Drugs market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 130.53 million in 2024.

Middle East and Africa Dementia Drugs Market

According to Cognitive Market Research, the global Dementia Drugs market size was estimated at USD 16215.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 324.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

• The GCC Countries Dementia Drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 138.80 million in 2024. Dementia Drugs sales flourish due to the presence of major market players.
• The Egypt Dementia Drugs market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 34.05 million in 2024.
• The South Africa Dementia Drugs market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 51.24 million in 2024. Dementia Drugs sales flourish in South Africa due to technological advancements, increasing demand, and regulatory support.
• The Turkey Dementia Drugs market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 27.89 million in 2024.
• The Nigeria Dementia Drugs market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 34.05 million in 2024.
• The Rest of the MEA Dementia Drugs market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 38.27 million in 2024.

Dementia Drugs Market Analysis

Dementia Drugs Market Type Segment Analysis

According to Cognitive Market Research, alzheimer’s disease stands out as the dominant category over the projected period. The increasing focus on research and development of effective Alzheimer's treatments is a key driver of market growth. The high prevalence of Alzheimer's disease, particularly among the elderly population, underscores the significant demand for dementia drugs. For instance, the Alzheimer's Association reported a substantial number of Americans living with Alzheimer's, a figure projected to rise dramatically. While there have been some advancements, such as the FDA approval of drugs like Aduhelm, the overall treatment landscape remains challenging. These factors collectively contribute to the expanding dementia drugs market.

Parkinson's Disease emerges as the fastest-growing category in the Dementia Drugs market. While Alzheimer's disease remains the most prevalent form, the increasing recognition of Parkinson's as a neurodegenerative condition with cognitive implications has driven substantial growth in this area. The incidence of Parkinson's disease increases with age, with the average age of onset being around 60. However, a significant number of cases occur in younger individuals. Approximately 10 million people globally are living with Parkinson's disease. The unique challenges posed by Parkinson's, including both motor and cognitive symptoms, have spurred research and development efforts, positioning it as a key focus within the dementia drug landscape.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Dementia Drugs Industry. Request a Free Sample PDF!

Dementia Drugs Market Application Segment Analysis

According to Cognitive Market Research, the dominant category is MAO inhibitors. MAO inhibitors were once used to treat certain types of dementia, particularly those associated with Parkinson's disease. These drugs work by increasing levels of important brain chemicals. However, their use has declined due to significant side effects and the development of newer, safer treatment options. While they still have a limited role in specific cases, MAO inhibitors are no longer considered a primary treatment for dementia.

The fastest-growing category in the Dementia Drugs market is Glutamate inhibitors represent a promising avenue for treating dementia, particularly Alzheimer's disease. By blocking the excessive activity of glutamate, a key neurotransmitter, these drugs aim to protect brain cells from damage. While research is ongoing, the potential benefits of glutamate inhibitors in slowing disease progression and improving patients' lives have made this drug class a major focus for pharmaceutical companies.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion